FIELD: biotechnology.
SUBSTANCE: invention discloses novel modified NKG2D ligands with attached polypeptides having specific target binding properties, for example, antibodies or variable antibody fragments selectively delivered to chimeric antigen receptors (CAR) containing modified, non-natural NKG2D receptors on modified mammalian cells.
EFFECT: invention can be used when producing CAR-cells capable of destroying HIV-infected cells.
10 cl, 14 ex, 13 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| COMPOSITIONS BASED ON NON-NATURAL BASE PAIRS AND METHODS OF THEIR USE | 2018 |
|
RU2799441C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
